Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.

Zhang N, Liu L, Dumitru CD, Cummings NR, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, Mallem MR, Ou Y, Patel RN, Vo K, Wang H, Burnina I, Choi BK, Huber HE, Stadheim TA, Zha D.

MAbs. 2011 May-Jun;3(3):289-98. Epub 2011 May 1.

2.

Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.

Aste-Am├ęzaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE.

PLoS One. 2010 Feb 8;5(2):e9094. doi: 10.1371/journal.pone.0009094.

3.

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.

Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, Watkins A, Bilodeau M, Hoffman J, Sanderson P, Hartman G, Mahan E, Prueksaritanont T, Jiang G, She QB, Rosen N, Sepp-Lorenzino L, Defeo-Jones D, Huber HE.

Cancer Biol Ther. 2010 Apr 1;9(7):493-503. Epub 2010 Apr 1.

4.

Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.

Li Y, Liang J, Siu T, Hu E, Rossi MA, Barnett SF, Defeo-Jones D, Jones RE, Robinson RG, Leander K, Huber HE, Mittal S, Cosford N, Prasit P.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):834-6. doi: 10.1016/j.bmcl.2008.12.017. Epub 2008 Dec 7.

PMID:
19097777
5.

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N.

PLoS One. 2008 Aug 26;3(8):e3065. doi: 10.1371/journal.pone.0003065.

6.

Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.

Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB, Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, Hartman GD.

J Med Chem. 2008 Jul 24;51(14):4239-52. doi: 10.1021/jm800386y. Epub 2008 Jun 25.

PMID:
18578472
7.

Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.

Bilodeau MT, Balitza AE, Hoffman JM, Manley PJ, Barnett SF, Defeo-Jones D, Haskell K, Jones RE, Leander K, Robinson RG, Smith AM, Huber HE, Hartman GD.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3178-82. doi: 10.1016/j.bmcl.2008.04.074. Epub 2008 May 1.

PMID:
18479914
8.

Rapid assembly of diverse and potent allosteric Akt inhibitors.

Wu Z, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Kohl NE, Hartman GD, Bilodeau MT.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2211-4. doi: 10.1016/j.bmcl.2007.10.023. Epub 2007 Oct 17.

PMID:
18296048
9.

Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.

Hartnett JC, Barnett SF, Bilodeau MT, Defeo-Jones D, Hartman GD, Huber HE, Jones RE, Kral AM, Robinson RG, Wu Z.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2194-7. doi: 10.1016/j.bmcl.2007.12.040. Epub 2007 Dec 23.

PMID:
18294842
10.

Development of pyridopyrimidines as potent Akt1/2 inhibitors.

Wu Z, Hartnett JC, Neilson LA, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Hartman GD, Bilodeau MT.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1274-9. doi: 10.1016/j.bmcl.2008.01.054. Epub 2008 Jan 19.

PMID:
18249537
11.

Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.

Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huber HE, Duggan ME, Lindsley CW.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):49-53. Epub 2007 Nov 13.

PMID:
18054229
12.

Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.

Garbaccio RM, Tasber ES, Neilson LA, Coleman PJ, Fraley ME, Olson C, Bergman J, Torrent M, Buser CA, Rickert K, Walsh ES, Hamilton K, Lobell RB, Tao W, South VJ, Diehl RE, Davide JP, Yan Y, Kuo LC, Li C, Prueksaritanont T, Fernandez-Metzler C, Mahan EA, Slaughter DE, Salata JJ, Kohl NE, Huber HE, Hartman GD.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5671-6. Epub 2007 Aug 21.

PMID:
17804233
13.

Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.

Cox CD, Breslin MJ, Whitman DB, Coleman PJ, Garbaccio RM, Fraley ME, Zrada MM, Buser CA, Walsh ES, Hamilton K, Lobell RB, Tao W, Abrams MT, South VJ, Huber HE, Kohl NE, Hartman GD.

Bioorg Med Chem Lett. 2007 May 15;17(10):2697-702. Epub 2007 Mar 6.

PMID:
17395460
14.

Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.

Fraley ME, Garbaccio RM, Arrington KL, Hoffman WF, Tasber ES, Coleman PJ, Buser CA, Walsh ES, Hamilton K, Fernandes C, Schaber MD, Lobell RB, Tao W, South VJ, Yan Y, Kuo LC, Prueksaritanont T, Shu C, Torrent M, Heimbrook DC, Kohl NE, Huber HE, Hartman GD.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1775-9. Epub 2006 Jan 24.

PMID:
16439123
15.

Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.

Garbaccio RM, Fraley ME, Tasber ES, Olson CM, Hoffman WF, Arrington KL, Torrent M, Buser CA, Walsh ES, Hamilton K, Schaber MD, Fernandes C, Lobell RB, Tao W, South VJ, Yan Y, Kuo LC, Prueksaritanont T, Slaughter DE, Shu C, Heimbrook DC, Kohl NE, Huber HE, Hartman GD.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1780-3. Epub 2006 Jan 24.

PMID:
16439122
16.

Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.

Cox CD, Breslin MJ, Mariano BJ, Coleman PJ, Buser CA, Walsh ES, Hamilton K, Huber HE, Kohl NE, Torrent M, Yan Y, Kuo LC, Hartman GD.

Bioorg Med Chem Lett. 2005 Apr 15;15(8):2041-5.

PMID:
15808464
17.

Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.

DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, Zhao Z, Huber HE, Jones RE.

Mol Cancer Ther. 2005 Feb;4(2):271-9.

18.

Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.

Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME, Lindsley CW.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):905-9.

PMID:
15686884
19.

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.

PMID:
15664853
20.

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.

Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J, McAvoy EM, Nahas DD, Robinson RG, Huber HE.

Biochem J. 2005 Jan 15;385(Pt 2):399-408.

21.

Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.

Dinsmore CJ, Zartman CB, Bergman JM, Abrams MT, Buser CA, Culberson JC, Davide JP, Ellis-Hutchings M, Fernandes C, Graham SL, Hartman GD, Huber HE, Lobell RB, Mosser SD, Robinson RG, Williams TM.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):639-43.

PMID:
14741259
22.

Inhibition of a mitotic motor protein: where, how, and conformational consequences.

Yan Y, Sardana V, Xu B, Homnick C, Halczenko W, Buser CA, Schaber M, Hartman GD, Huber HE, Kuo LC.

J Mol Biol. 2004 Jan 9;335(2):547-54.

PMID:
14672662
23.

Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.

deSolms SJ, Ciccarone TM, MacTough SC, Shaw AW, Buser CA, Ellis-Hutchings M, Fernandes C, Hamilton KA, Huber HE, Kohl NE, Lobell RB, Robinson RG, Tsou NN, Walsh ES, Graham SL, Beese LS, Taylor JS.

J Med Chem. 2003 Jul 3;46(14):2973-84.

PMID:
12825937
24.

The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.

Tucker TJ, Abrams MT, Buser CA, Davide JP, Ellis-Hutchings M, Fernandes C, Gibbs JB, Graham SL, Hartman GD, Huber HE, Liu D, Lobell RB, Lumma WC, Robinson RG, Sisko JT, Smith AM.

Bioorg Med Chem Lett. 2002 Aug 5;12(15):2027-30.

PMID:
12113834
25.

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

Bell IM, Gallicchio SN, Abrams M, Beese LS, Beshore DC, Bhimnathwala H, Bogusky MJ, Buser CA, Culberson JC, Davide J, Ellis-Hutchings M, Fernandes C, Gibbs JB, Graham SL, Hamilton KA, Hartman GD, Heimbrook DC, Homnick CF, Huber HE, Huff JR, Kassahun K, Koblan KS, Kohl NE, Lobell RB, Lynch JJ Jr, Robinson R, Rodrigues AD, Taylor JS, Walsh ES, Williams TM, Zartman CB.

J Med Chem. 2002 Jun 6;45(12):2388-409.

PMID:
12036349
26.

Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I.

Nguyen DN, Stump CA, Walsh ES, Fernandes C, Davide JP, Ellis-Hutchings M, Robinson RG, Williams TM, Lobell RB, Huber HE, Buser CA.

Bioorg Med Chem Lett. 2002 May 6;12(9):1269-73.

PMID:
11965368
27.

Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.

Dinsmore CJ, Bogusky MJ, Culberson JC, Bergman JM, Homnick CF, Zartman CB, Mosser SD, Schaber MD, Robinson RG, Koblan KS, Huber HE, Graham SL, Hartman GD, Huff JR, Williams TM.

J Am Chem Soc. 2001 Mar 7;123(9):2107-8. No abstract available.

PMID:
11456854
28.

Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.

Bergman JM, Abrams MT, Davide JP, Greenberg IB, Robinson RG, Buser CA, Huber HE, Koblan KS, Kohl NE, Lobell RB, Graham SL, Hartman GD, Williams TM, Dinsmore CJ.

Bioorg Med Chem Lett. 2001 Jun 4;11(11):1411-5.

PMID:
11378366
29.

2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.

Trotter BW, Quigley AG, Lumma WC, Sisko JT, Walsh ES, Hamann CS, Robinson RG, Bhimnathwala H, Kolodin DG, Zheng W, Buser CA, Huber HE, Lobell RB, Kohl NE, Williams TM, Graham SL, Dinsmore CJ.

Bioorg Med Chem Lett. 2001 Apr 9;11(7):865-9.

PMID:
11294379
30.

Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors.

Huber HE, Robinson RG, Watkins A, Nahas DD, Abrams MT, Buser CA, Lobell RB, Patrick D, Anthony NJ, Dinsmore CJ, Graham SL, Hartman GD, Lumma WC, Williams TM, Heimbrook DC.

J Biol Chem. 2001 Jul 6;276(27):24457-65. Epub 2001 Mar 26.

31.

Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK.

Zhao A, Lee SH, Mojena M, Jenkins RG, Patrick DR, Huber HE, Goetz MA, Hensens OD, Zink DL, Vilella D, Dombrowski AW, Lingham RB, Huang L.

J Antibiot (Tokyo). 1999 Dec;52(12):1086-94.

32.

Retinoblastoma protein reverses DNA bending by transcription factor E2F.

Huber HE, Goodhart PJ, Huang PS.

J Biol Chem. 1994 Mar 4;269(9):6999-7005.

33.

Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.

Ivey-Hoyle M, Conroy R, Huber HE, Goodhart PJ, Oliff A, Heimbrook DC.

Mol Cell Biol. 1993 Dec;13(12):7802-12.

34.

Transcription factor E2F binds DNA as a heterodimer.

Huber HE, Edwards G, Goodhart PJ, Patrick DR, Huang PS, Ivey-Hoyle M, Barnett SF, Oliff A, Heimbrook DC.

Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3525-9.

35.

Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.

Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, Garsky VM, Oliff A, Heimbrook DC.

Mol Cell Biol. 1993 Feb;13(2):953-60.

36.

Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product.

Stirdivant SM, Huber HE, Patrick DR, Defeo-Jones D, McAvoy EM, Garsky VM, Oliff A, Heimbrook DC.

Mol Cell Biol. 1992 May;12(5):1905-14.

37.

Purification and characterization of a functionally homogeneous 60-kDa species of the retinoblastoma gene product.

Edwards GM, Huber HE, DeFeo-Jones D, Vuocolo G, Goodhart PJ, Maigetter RZ, Sanyal G, Oliff A, Heimbrook DC.

J Biol Chem. 1992 Apr 25;267(12):7971-4. Erratum in: J Biol Chem 1992 Jul 5;267(19):13780.

38.

Specific N-methylations of HPV-16 E7 peptides alter binding to the retinoblastoma suppressor protein.

Jones RE, Heimbrook DC, Huber HE, Wegrzyn RJ, Rotberg NS, Stauffer KJ, Lumma PK, Garsky VM, Oliff A.

J Biol Chem. 1992 Jan 15;267(2):908-12.

39.

Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product.

Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, Huber HE, Oliff A.

Nature. 1991 Jul 18;352(6332):251-4.

PMID:
1857421
40.
41.
42.

Escherichia coli dGTP triphosphohydrolase is inhibited by gene 1.2 protein of bacteriophage T7.

Huber HE, Beauchamp BB, Richardson CC.

J Biol Chem. 1988 Sep 25;263(27):13549-56.

43.

Escherichia coli thioredoxin stabilizes complexes of bacteriophage T7 DNA polymerase and primed templates.

Huber HE, Tabor S, Richardson CC.

J Biol Chem. 1987 Nov 25;262(33):16224-32.

44.
46.

Site-specific DNA inversion is enhanced by a DNA sequence element in cis.

Huber HE, Iida S, Arber W, Bickle TA.

Proc Natl Acad Sci U S A. 1985 Jun;82(11):3776-80.

47.
48.

Optical characterization of a low solubility organic compound.

Huber HE.

J Pharm Sci. 1981 Oct;70(10):1152-4.

PMID:
7299651
49.

Osmolality of parenteral solutions.

Huber HE, Streng WH, Tan HG.

J Pharm Sci. 1979 Aug;68(8):1028-32.

PMID:
480158
50.

Relationship between osmolality and osmolarity.

Streng WH, Huber HE, Carstensen JT.

J Pharm Sci. 1978 Mar;67(3):384-6.

PMID:
641729

Supplemental Content

Loading ...
Support Center